Over the next few years, we’ll likely be seeing more stories about things like Merck’s $90 million translational research center for scientists, entrepreneurs and venture capitalists; Sanofi’s partnership with Third Rock Ventures to launch a new biotech company; and Johnson & Johnson, GSK and Index Ventures’ new fund.
That’s because open innovation and cooperation in the pharmaceutical industry will continue to gain traction as patent losses and R&D cutbacks force drug companies to look outside of their own walls for promising technologies, according to a new report from GBI Research.
To read the full, original article click on this link: More open innovation, collaboration needed to fill pharma’s pipelines
